Company Overview and News

 
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

2018-05-08 globenewswire
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the successful completion of its colitis preclinical program at the University of Zürich, Switzerland.

1
Immuron CEO to Present at RedChip Global Online Growth Conference

2018-04-23 globenewswire
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is pleased to advise shareholders and investors that CEO Dr Jerry Kanellos, will be presenting at 10:00 am USET on Wednesday April 24th, 2018 at this month’s US RedChip Global Online Growth Conference.

 
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets

2018-04-23 globenewswire
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the sales results of its commercially available, over-the-counter gastrointestinal and digestive health supplement Travelan®, for the third fiscal quarter ending March 31, 2018.

 
S&P/ASX 200 - market closes on a high; trade dominates

2018-03-08 proactiveinvestors.com.au
The S&P/ASX 200 ended the session in positive territory but off its session high on a day dominated by foreign trade as the index ended up 35.10 at 5,937.10.

3
Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

2018-03-08 proactiveinvestors.com.au
Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

 
Immuron achieves strong sales growth for travellers’ diarrhoea product

2018-02-16 proactiveinvestors.com.au
Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) flag-ship product Travelan® has achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

 
Immuron concludes promising fatty liver disease clinical study

2017-11-09 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC, NASDAQ:IMRN) has concluded the phase II study of IMM‐124E for the treatment of NASH (non-alcoholic steatohepatitis), with the results expected in Q1 2018.

 
Immuron set to commence Clostridium Difficile Infection study in Israel

2017-08-09 proactiveinvestors.com.au
Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

 
Immuron targets cash injection

2017-06-08 proactiveinvestors.com.au
Immuron (ASX:IMC) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Immuron looks to NASDAQ

2017-05-30 proactiveinvestors.com.au
Immuron (ASX:IMC) has been granted a trading halt by the ASX, with its shares placed in pre-open.

 
Immuron gets ready to begin clinical trial of new drug candidate

2017-05-10 proactiveinvestors.com.au
Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI).

 
Immuron enrols first patient in paediatric fatty liver trial in the U.S.

2017-02-06 proactiveinvestors.com.au
Immuron (ASX:IMC) has enrolled the first patient for its paediatric NAFLD (non-alcoholic fatty liver disease) Phase II trial conducted by Emory University in Georgia, U.S.

 
Immuron Ltd to develop vaccine for deadly bacillary dysentery with U.S. Army research unit

2016-06-21 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

 
Immuron Ltd in ASX trading halt

2016-05-26 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

 
Immuron Ltd has no safety issues in Phase II fatty liver trial

2016-05-25 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...